A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290
A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290
This study assesses the long-term safety and efficacy of adalimumab in pediatric subjects with ulcerative colitis.
Inclusion Criteria:
- Subject must have successfully enrolled and completed M11-290 study
Exclusion Criteria:
- Subject considered by the investigator, for any reason, to be an unsuitable candidate
Kurume-shi, Fukuoka 830-0011, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Setagaya-ku, Tokyo 157-8535, Japan
Krakow, Lesser Poland Voivodeship 30-663, Poland
Wroclaw, Lower Silesian Voivodeship 50-369, Poland
London, Greater London E1 2ES, United Kingdom